YU58103A - Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona - Google Patents
Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilonaInfo
- Publication number
- YU58103A YU58103A YU58103A YUP58103A YU58103A YU 58103 A YU58103 A YU 58103A YU 58103 A YU58103 A YU 58103A YU P58103 A YUP58103 A YU P58103A YU 58103 A YU58103 A YU 58103A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- epothilones
- dosage forms
- pharmaceutical dosage
- oral administration
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pronalasci su povezani sa postupcima povećanja bioraspoloživosti oralno primenjenih epotilona. Primenjeni epotiloni su smanjene bioraspoloživosti da daju farmakološki efekat. Buduća istraživanja povezana su sa farmaceutskim jedinjenjima, farmaceutskim doziranim oblicima i kitovima za korišćenje u ovim pronalascima.[The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26422801P | 2001-01-25 | 2001-01-25 | |
US29001901P | 2001-05-11 | 2001-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU58103A true YU58103A (sh) | 2006-03-03 |
Family
ID=26950349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU58103A YU58103A (sh) | 2001-01-25 | 2002-01-25 | Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona |
Country Status (26)
Country | Link |
---|---|
US (2) | US6576651B2 (sh) |
EP (1) | EP1361877A1 (sh) |
JP (1) | JP2004528287A (sh) |
KR (1) | KR20040025888A (sh) |
CN (1) | CN1268336C (sh) |
AR (1) | AR035078A1 (sh) |
BG (1) | BG108027A (sh) |
BR (1) | BR0206695A (sh) |
CA (1) | CA2434584A1 (sh) |
CZ (1) | CZ20032023A3 (sh) |
EE (1) | EE200300329A (sh) |
HR (1) | HRP20030674A2 (sh) |
HU (1) | HUP0303800A3 (sh) |
IL (1) | IL156759A0 (sh) |
IS (1) | IS6892A (sh) |
MX (1) | MXPA03006476A (sh) |
NO (1) | NO20033343L (sh) |
NZ (1) | NZ526871A (sh) |
PE (1) | PE20020853A1 (sh) |
PL (1) | PL368636A1 (sh) |
RU (1) | RU2291695C2 (sh) |
SK (1) | SK9212003A3 (sh) |
TW (1) | TWI250017B (sh) |
UY (1) | UY27138A1 (sh) |
WO (2) | WO2002058699A1 (sh) |
YU (1) | YU58103A (sh) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP0977563B1 (en) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
KR100804873B1 (ko) | 1999-06-10 | 2008-02-20 | 얼라이드시그날 인코퍼레이티드 | 포토리소그래피용 sog 반사방지 코팅 |
US6824879B2 (en) | 1999-06-10 | 2004-11-30 | Honeywell International Inc. | Spin-on-glass anti-reflective coatings for photolithography |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
HUP0302567A2 (hu) * | 2001-01-25 | 2003-12-29 | Bristol-Myers Squibb Co. | Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra |
WO2002066038A1 (en) | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
ES2384789T3 (es) * | 2001-03-14 | 2012-07-12 | Bristol-Myers Squibb Company | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas |
CN1606713B (zh) | 2001-11-15 | 2011-07-06 | 霍尼韦尔国际公司 | 用于照相平版印刷术的旋涂抗反射涂料 |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN1759115A (zh) | 2002-08-23 | 2006-04-12 | 索隆-基特林癌症研究协会 | 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途 |
AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
EP2792363B1 (en) * | 2003-08-26 | 2016-06-29 | Shire Biopharmaceuticals Holdings Ireland Limited | Pharmaceutical formulation comprising lanthanum compounds |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
AU2004291107B2 (en) | 2003-11-14 | 2010-09-30 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
US8053159B2 (en) | 2003-11-18 | 2011-11-08 | Honeywell International Inc. | Antireflective coatings for via fill and photolithography applications and methods of preparation thereof |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
PE20061058A1 (es) | 2004-11-18 | 2006-10-13 | Bristol Myers Squibb Co | Composicion farmaceutica que comprende ixabepilona y proceso de preparacion |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
US8642246B2 (en) | 2007-02-26 | 2014-02-04 | Honeywell International Inc. | Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof |
MX2010011209A (es) | 2008-04-24 | 2010-11-12 | Squibb Bristol Myers Co | Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer. |
US8557877B2 (en) | 2009-06-10 | 2013-10-15 | Honeywell International Inc. | Anti-reflective coatings for optically transparent substrates |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US8864898B2 (en) | 2011-05-31 | 2014-10-21 | Honeywell International Inc. | Coating formulations for optical elements |
CN102276433B (zh) * | 2011-06-30 | 2016-04-20 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
JP6803842B2 (ja) | 2015-04-13 | 2020-12-23 | ハネウェル・インターナショナル・インコーポレーテッドHoneywell International Inc. | オプトエレクトロニクス用途のためのポリシロキサン製剤及びコーティング |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE59609305D1 (de) | 1995-11-17 | 2002-07-11 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Herstellung |
SI0932399T1 (sl) * | 1996-03-12 | 2006-10-31 | Pg Txl Co Lp | Vodotopna paklitakselna predzdravila |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19636343C1 (de) * | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
PT941227E (pt) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
EP0977563B1 (en) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
EP1201666A3 (de) | 1997-02-25 | 2003-03-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Seitenkettenmodifizierte Epothilone |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
JP4065573B2 (ja) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
AU8542898A (en) | 1997-07-16 | 1999-02-10 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
DK1005465T3 (da) | 1997-08-09 | 2007-11-05 | Bayer Schering Pharma Ag | Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
JP4644364B2 (ja) | 1998-02-05 | 2011-03-02 | ノバルティス アーゲー | エポシロン組成物 |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
AU2795000A (en) | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
EA009206B1 (ru) | 1999-02-18 | 2007-12-28 | Шеринг Акциенгезельшафт | Производные 16-галогенэпотилона и их фармацевтическое использование |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
IL156578A0 (en) | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
ES2384789T3 (es) | 2001-03-14 | 2012-07-12 | Bristol-Myers Squibb Company | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas |
-
2002
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Application Discontinuation
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Application Discontinuation
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 PL PL02368636A patent/PL368636A1/xx not_active Application Discontinuation
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Application Discontinuation
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
-
2003
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-08-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
-
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
KR20040025888A (ko) | 2004-03-26 |
JP2004528287A (ja) | 2004-09-16 |
NO20033343L (no) | 2003-09-24 |
HUP0303800A2 (hu) | 2004-03-29 |
UY27138A1 (es) | 2002-08-30 |
AU2002253880B2 (en) | 2006-11-09 |
CA2434584A1 (en) | 2002-08-01 |
SK9212003A3 (en) | 2004-11-03 |
PE20020853A1 (es) | 2002-09-27 |
TWI250017B (en) | 2006-03-01 |
NO20033343D0 (no) | 2003-07-24 |
NZ526871A (en) | 2006-01-27 |
CN1268336C (zh) | 2006-08-09 |
CN1498106A (zh) | 2004-05-19 |
IS6892A (is) | 2003-07-24 |
EE200300329A (et) | 2003-10-15 |
MXPA03006476A (es) | 2003-09-22 |
HRP20030674A2 (en) | 2005-06-30 |
US6576651B2 (en) | 2003-06-10 |
HUP0303800A3 (en) | 2005-02-28 |
IL156759A0 (en) | 2004-02-08 |
RU2003126174A (ru) | 2005-02-27 |
EP1361877A1 (en) | 2003-11-19 |
PL368636A1 (en) | 2005-04-04 |
RU2291695C2 (ru) | 2007-01-20 |
BG108027A (bg) | 2004-12-30 |
CZ20032023A3 (cs) | 2005-03-16 |
AR035078A1 (es) | 2004-04-14 |
BR0206695A (pt) | 2004-04-20 |
US20020177615A1 (en) | 2002-11-28 |
WO2002058701A1 (en) | 2002-08-01 |
USRE40387E1 (en) | 2008-06-17 |
WO2002058699A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU58103A (sh) | Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona | |
NO20044452L (no) | Oral administrering av epotiloner | |
IL166489A (en) | Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
AU2003229555A1 (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
BR0111868A (pt) | Composições farmacêuticas | |
WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
HUP0402178A2 (hu) | 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
HUP0301082A2 (hu) | Új polimorf olanzapine hidroklorid sók, eljárás ezek előállítására, az ezeket tartalmazó gyógyászati készítmények és felhasználásuk | |
WO2005009407A3 (en) | Oral pharmaceutical formulations of olanzapine | |
DE602004016963D1 (en) | Therapeutisches system mit amoxicillin und clavulansäure | |
HK1102021A1 (en) | Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative | |
TW200517127A (en) | Novel composition | |
WO2005051349A3 (en) | Pharmaceutical compositions of mirtazapine | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
EP1565162A4 (en) | MICROEMULSION COMPOSITION FOR ORAL ADMINISTRATION OF BIPHENYLDIMETHYLDICARBOXYLATE | |
CA2548078A1 (en) | Pharmaceutical formulations of camptothecins and process for making same | |
WO2005051489A3 (en) | Fast dissolving solid oral dosage forms of galanthamine | |
HUP0301337A2 (hu) | Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk | |
HUP0300032A2 (en) | Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition | |
WO2005115092A3 (en) | Micronized oral pharmaceutical composition | |
MY145885A (en) | Controlled release formulations for oral administration |